Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss, and emerging research has focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer
For weight loss, noticeable results may take longer and are most effective when combined with diet and exercise changes
This class of medications is becoming a household name, not only for their implications for weight loss but also for their effect on cardiovascular disease
Additionally, retatrutide can aid in weight management
These include: Acute gallbladder disease (added to warning label in March 2022) Acute problems Acute pancreatitis Diabetic retinopathy complications in patients with type 2 Diabetes Gastrointestinal obstruction Ileus (added to the warning label in September 2023) Heart rate increase Hypoglycemia Possible thyroid tumors, including cancer Severe allergic reactions and hypersensitivity reactions, including anaphylaxis and angioedema Suicidal thoughts or behavior If you are taking Wegovy or any other GLP-1 drug like Mounjaro or Rybelsus , contact your doctor if you experience new or worsening side effects
US$ 25.03
US$ 22.56
US$ 26.95
US$ 24.72
US$ 21.91
US$ 27.66
